Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 482

1.

Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations.

Maritan M, Ambrosetti A, Oberti L, Barbiroli A, Diomede L, Romeo M, Lavatelli F, Sormanni P, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Amyloid. 2019;26(sup1):105-106. doi: 10.1080/13506129.2019.1583185. No abstract available.

PMID:
31343361
2.

The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis.

Oberti L, Maritan M, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Amyloid. 2019;26(sup1):107-108. doi: 10.1080/13506129.2019.1583187. No abstract available.

PMID:
31343357
3.

Predicting survival in light chain amyloidosis.

Palladini G, Milani P, Merlini G.

Haematologica. 2019 Jul;104(7):1294-1296. doi: 10.3324/haematol.2019.218859. No abstract available.

4.

Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS).

Lucherini OM, Vitale A, Obici L, Sota J, Frediani B, Merlini G, Rigante D, Cantarini L.

Clin Exp Rheumatol. 2019 May 30. [Epub ahead of print] No abstract available.

PMID:
31172924
5.

Human osteogenic differentiation in Space: proteomic and epigenetic clues to better understand osteoporosis.

Gambacurta A, Merlini G, Ruggiero C, Diedenhofen G, Battista N, Bari M, Balsamo M, Piccirillo S, Valentini G, Mascetti G, Maccarrone M.

Sci Rep. 2019 Jun 6;9(1):8343. doi: 10.1038/s41598-019-44593-6.

6.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients.

Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, Lavatelli F.

Blood. 2019 Jul 18;134(3):320-323. doi: 10.1182/blood.2019000420. Epub 2019 Jun 6. No abstract available.

PMID:
31171502
7.

A revised international prognostic score system for Waldenström's macroglobulinemia.

Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, Dimopoulos MA.

Leukemia. 2019 May 22. doi: 10.1038/s41375-019-0431-y. [Epub ahead of print]

PMID:
31118465
8.

Treatment of cardiac transthyretin amyloidosis: an update.

Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferović PM, Barison A, Castiglione V, Vergaro G, Giannoni A, Passino C, Merlini G.

Eur Heart J. 2019 May 20. pii: ehz298. doi: 10.1093/eurheartj/ehz298. [Epub ahead of print]

PMID:
31111153
9.

Stabilization of amyloidogenic immunoglobulin light chains by small molecules.

Morgan GJ, Yan NL, Mortenson DE, Rennella E, Blundon JM, Gwin RM, Lin CY, Stanfield RL, Brown SJ, Rosen H, Spicer TP, Fernandez-Vega V, Merlini G, Kay LE, Wilson IA, Kelly JW.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8360-8369. doi: 10.1073/pnas.1817567116. Epub 2019 Apr 10.

PMID:
30971495
10.

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.

Swuec P, Lavatelli F, Tasaki M, Paissoni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, Palladini G, Merlini G, Ricagno S, Bolognesi M.

Nat Commun. 2019 Mar 20;10(1):1269. doi: 10.1038/s41467-019-09133-w.

11.

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.

Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD.

JAMA Cardiol. 2019 May 1;4(5):466-472. doi: 10.1001/jamacardio.2019.0849.

12.

Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration.

Mishra S, Joshi S, Ward JE, Buys EP, Mishra D, Mishra D, Morgado I, Fisch S, Lavatelli F, Merlini G, Dorbala S, MacRae CA, Liao R.

Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1158-H1166. doi: 10.1152/ajpheart.00788.2018. Epub 2019 Mar 15.

PMID:
30875258
13.

New Insights Into a Multifaceted Disease.

Nuvolone M, Merlini G.

Mayo Clin Proc. 2019 Mar;94(3):388-390. doi: 10.1016/j.mayocp.2019.01.029. No abstract available.

PMID:
30832787
14.

Correction: Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, Kourelis T, Arendt B, Merlini G, Ramirez-Alvarado M, Dispenzieri A.

Leukemia. 2019 Apr;33(4):1060. doi: 10.1038/s41375-019-0405-0.

PMID:
30814620
15.

Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer.

Ciani O, Cucciniello M, Petracca F, Apolone G, Merlini G, Novello S, Pedrazzoli P, Zilembo N, Broglia C, Capelletto E, Garassino M, Nicod E, Tarricone R.

BMJ Open. 2019 Feb 15;9(2):e025483. doi: 10.1136/bmjopen-2018-025483.

16.

ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis.

Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, Nuvolone M, Palladini G, Merlini G, Lavatelli F, Natalello A.

Anal Chem. 2019 Feb 19;91(4):2894-2900. doi: 10.1021/acs.analchem.8b05008. Epub 2019 Feb 4.

PMID:
30676723
17.

Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.

Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M.

Amyloid. 2019 Mar;26(1):10-14. doi: 10.1080/13506129.2018.1554563. Epub 2019 Jan 24.

PMID:
30675806
18.

When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression.

Palladini G, Merlini G.

Blood Adv. 2019 Jan 22;3(2):212-215. doi: 10.1182/bloodadvances.2018021253. No abstract available.

19.

Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice.

Nuvolone M, Merlini G.

Kidney Int. 2019 Feb;95(2):258-260. doi: 10.1016/j.kint.2018.11.003.

PMID:
30665564
20.

A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options.

Moutafi M, Ziogas DC, Michopoulos S, Bagratuni T, Vasileiou V, Verga L, Merlini G, Palladini G, Matsouka C, Dimopoulos MA, Kastritis E.

BMC Med Genet. 2019 Jan 21;20(1):23. doi: 10.1186/s12881-019-0755-5.

21.

Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.

Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P.

Amyloid. 2018 Dec;25(4):215-219. doi: 10.1080/13506129.2018.1549825. Epub 2019 Jan 7.

PMID:
30614283
22.

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O.

Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831.

PMID:
30586695
23.

High sensitivity M-protein detection in a case of light-chain cardiac amyloidosis without evidence of plasma cell dyscrasia.

Saadalla AM, Singh A, Barnidge D, Kohlhagen M, Merlini G, Falk RH, Murray D.

Am J Hematol. 2019 May;94(5):619-621. doi: 10.1002/ajh.25383. Epub 2019 Jan 8. No abstract available.

PMID:
30575105
24.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7.

PMID:
30568288
25.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30510265
26.

Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?

Obici L, Merlini G.

Mayo Clin Proc. 2018 Nov;93(11):1546-1548. doi: 10.1016/j.mayocp.2018.09.008. No abstract available.

PMID:
30392540
27.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
28.

Therapies for cardiac light chain amyloidosis: An update.

Aimo A, Buda G, Fontana M, Barison A, Vergaro G, Emdin M, Merlini G.

Int J Cardiol. 2018 Nov 15;271:152-160. doi: 10.1016/j.ijcard.2018.05.018. Review.

PMID:
30223349
29.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

30.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Milani P, Schönland S, Merlini G, Kimmich C, Foli A, Dittrich T, Basset M, Müller-Tidow C, Bochtler T, Palladini G, Hegenbart U.

Blood. 2018 Nov 1;132(18):1988-1991. doi: 10.1182/blood-2018-04-845396. Epub 2018 Aug 14. No abstract available.

PMID:
30108065
31.

MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms.

Kourelis T, Murray DL, Dasari S, Kumar S, Barnidge D, Madden B, Arendt B, Milani P, Merlini G, Ramirez-Alvarado M, Kyle RA, Dispenzieri A.

Am J Hematol. 2018 Nov;93(11):E368-E370. doi: 10.1002/ajh.25244. Epub 2018 Sep 21. No abstract available.

PMID:
30105838
32.

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastritis E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E.

Leukemia. 2018 Sep;32(9):1883-1898. doi: 10.1038/s41375-018-0209-7. Epub 2018 Jul 23. Review.

33.

Outrageous prices of orphan drugs: a call for collaboration.

Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, Kääriäinen H, Garattini S, Hollak CE, Remuzzi G; Second Workshop on Orphan Drugs participants.

Lancet. 2018 Sep 1;392(10149):791-794. doi: 10.1016/S0140-6736(18)31069-9. Epub 2018 Jul 20. No abstract available.

PMID:
30037734
34.

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications.

Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, Merlini G.

Blood. 2018 Oct 4;132(14):1478-1485. doi: 10.1182/blood-2018-04-839480. Epub 2018 Jul 16. Review.

PMID:
30012636
35.

Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

Kumar S, Murray D, Dasari S, Milani P, Barnidge D, Madden B, Kourelis T, Arendt B, Merlini G, Ramirez-Alvarado M, Dispenzieri A.

Leukemia. 2019 Jan;33(1):254-257. doi: 10.1038/s41375-018-0194-x. Epub 2018 Jul 6. No abstract available. Erratum in: Leukemia. 2019 Apr;33(4):1060.

PMID:
29977017
36.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

37.

Novel Therapies in Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Kidney Int Rep. 2017 Nov 28;3(3):530-541. doi: 10.1016/j.ekir.2017.11.017. eCollection 2018 May. Review.

38.

Management of the elderly patient with AL amyloidosis.

Nuvolone M, Milani P, Palladini G, Merlini G.

Eur J Intern Med. 2018 Dec;58:48-56. doi: 10.1016/j.ejim.2018.05.004. Epub 2018 May 23. Review.

PMID:
29801808
39.

Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M.

Circ Cardiovasc Imaging. 2018 May;11(5):e006588. doi: 10.1161/CIRCIMAGING.117.006588.

40.

Light Chain Amyloidosis.

Milani P, Merlini G, Palladini G.

Mediterr J Hematol Infect Dis. 2018 Mar 1;10(1):e2018022. doi: 10.4084/MJHID.2018.022. eCollection 2018. Review.

41.

The elusive pathogenesis of Schnitzler syndrome.

Palladini G, Merlini G.

Blood. 2018 Mar 1;131(9):944-946. doi: 10.1182/blood-2018-01-824862. No abstract available.

42.

Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing.

Lavatelli F, Merlini G.

Proteomics. 2018 Apr;18(7):e1700353. doi: 10.1002/pmic.201700353. Epub 2018 Mar 8.

PMID:
29389069
43.

Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.

Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, Dimopoulos MA, Palladini G.

Blood. 2018 Apr 5;131(14):1568-1575. doi: 10.1182/blood-2017-12-819904. Epub 2018 Jan 31.

44.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

45.

New concepts in the treatment and diagnosis of amyloidosis.

Milani P, Palladini G, Merlini G.

Expert Rev Hematol. 2018 Feb;11(2):117-127. doi: 10.1080/17474086.2018.1424534. Epub 2018 Jan 10. Review.

PMID:
29307226
46.

AL amyloidosis: from molecular mechanisms to targeted therapies.

Merlini G.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):1-12. doi: 10.1182/asheducation-2017.1.1. Review.

47.

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.

Oberti L, Rognoni P, Barbiroli A, Lavatelli F, Russo R, Maritan M, Palladini G, Bolognesi M, Merlini G, Ricagno S.

Sci Rep. 2017 Dec 1;7(1):16809. doi: 10.1038/s41598-017-16953-7.

48.

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.

Imperlini E, Gnecchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, Lavatelli F.

Sci Rep. 2017 Nov 15;7(1):15661. doi: 10.1038/s41598-017-15424-3.

49.

Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.

Palladini G, Milani P, Foli A, Basset M, Russo F, Perlini S, Merlini G.

Blood. 2018 Feb 1;131(5):525-532. doi: 10.1182/blood-2017-04-780544. Epub 2017 Nov 3.

50.

Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.

Nuvolone M, Merlini G.

Expert Opin Ther Targets. 2017 Dec;21(12):1095-1110. doi: 10.1080/14728222.2017.1398235. Review.

PMID:
29076382

Supplemental Content

Loading ...
Support Center